Compare Abeona Therapeutics Inc (ABEO) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hasbro, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Hasbro, Inc. trades at $76.04 (market cap $10.86B). The key difference: Hasbro, Inc. is far larger — about 29.1× Abeona Therapeutics Inc's market cap, and Hasbro, Inc. pays a 3.65% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HAS | |
|---|---|---|
Market Cap | $373.32M | $10.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $105.88 |
52-Week Low | $4.17 | $70.95 |
Enterprise Value | $228.22M | $13.12B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Hasbro (HAS) trades at $76.73, down 4.27% on the day, with a bearish technical signal but oversold RSI readings suggesting potential reversal. The company reported a net loss of $322.4 million in 2025 despite revenue growth to $4.70 billion, with strong earnings beats in recent quarters. Analyst consensus is bullish with a $107.40 price target, while institutional sentiment remains mixed amid high debt levels and profitability challenges.
The outlook hinges on earnings execution and debt management, with upside from Wizards segment growth and digital initiatives. Key risks include sustained negative margins, $3.38 billion long-term debt burden, and consumer discretionary volatility. Near-term catalyst is Q2 2026 earnings on July 21, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
